These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 3127050)

  • 1. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease.
    Golbe LI; Lieberman AN; Muenter MD; Ahlskog JE; Gopinathan G; Neophytides AN; Foo SH; Duvoisin RC
    Clin Neuropharmacol; 1988 Feb; 11(1):45-55. PubMed ID: 3127050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind trial of R-(-)-deprenyl for the "on-off" effect complicating Parkinson's disease.
    Golbe LI; Duvoisin RC
    J Neural Transm Suppl; 1987; 25():123-9. PubMed ID: 3123598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deprenyl (selegiline) in the treatment of Parkinson's disease.
    Rinne UK
    Acta Neurol Scand Suppl; 1983; 95():107-11. PubMed ID: 6428141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L-deprenyl (selegiline) added to Sinemet CR in the management of Parkinson's disease patients with motor response fluctuations.
    Cedarbaum JM; Toy LH; Green-Parsons A
    Clin Neuropharmacol; 1991 Jun; 14(3):228-34. PubMed ID: 1906374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa.
    Schachter M; Marsden CD; Parkes JD; Jenner P; Testa B
    J Neurol Neurosurg Psychiatry; 1980 Nov; 43(11):1016-21. PubMed ID: 6777463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.
    Tetrud JW; Langston JW
    Science; 1989 Aug; 245(4917):519-22. PubMed ID: 2502843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deprenyl (selegiline) combined with levodopa and a decarboxylase inhibitor in the treatment of Parkinson's disease.
    Presthus J; Hajba A
    Acta Neurol Scand Suppl; 1983; 95():127-33. PubMed ID: 6428145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deprenyl in Parkinson's disease.
    Lees AJ; Shaw KM; Kohout LJ; Stern GM; Elsworth JD; Sandler M; Youdim MB
    Lancet; 1977 Oct; 2(8042):791-5. PubMed ID: 71602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of deprenyl and levodopa on the progression of Parkinson's disease.
    Olanow CW; Hauser RA; Gauger L; Malapira T; Koller W; Hubble J; Bushenbark K; Lilienfeld D; Esterlitz J
    Ann Neurol; 1995 Nov; 38(5):771-7. PubMed ID: 7486869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deprenyl in Parkinson disease.
    Eisler T; Teräväinen H; Nelson R; Krebs H; Weise V; Lake CR; Ebert MH; Whetzel N; Murphy DL; Kopin IJ; Calne DB
    Neurology; 1981 Jan; 31(1):19-23. PubMed ID: 6161320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. R-(-)-deprenyl as an adjuvant to levodopa in the treatment of Parkinson's disease.
    Rinne UK
    J Neural Transm Suppl; 1987; 25():149-55. PubMed ID: 3123601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selegiline (1-deprenyl) and low-dose levodopa treatment of Parkinson's disease. A double-blind crossover trial.
    Presthus J; Berstad J; Lien K
    Acta Neurol Scand; 1987 Sep; 76(3):200-3. PubMed ID: 3120487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New drugs for Parkinson's disease.
    Hodges LC; Rapp CG
    J Neurosci Nurs; 1990 Aug; 22(4):254-7. PubMed ID: 2144560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.
    Heinonen EH; Myllylä V
    Drug Saf; 1998 Jul; 19(1):11-22. PubMed ID: 9673855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. R-(-)-deprenyl in the treatment of end-of-dose akinesia.
    Ulm G; Fornadi F
    J Neural Transm Suppl; 1987; 25():163-72. PubMed ID: 3123603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
    Shoulson I; Oakes D; Fahn S; Lang A; Langston JW; LeWitt P; Olanow CW; Penney JB; Tanner C; Kieburtz K; Rudolph A;
    Ann Neurol; 2002 May; 51(5):604-12. PubMed ID: 12112107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deprenyl (selegiline) in combination treatment of Parkinson's disease.
    Gerstenbrand F; Ransmayr G; Poewe W
    Acta Neurol Scand Suppl; 1983; 95():123-6. PubMed ID: 6428144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deprenyl (selegiline) in the treatment of Parkinson's disease.
    Birkmayer W
    Acta Neurol Scand Suppl; 1983; 95():103-5. PubMed ID: 6428140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selegiline use to prevent progression of Parkinson's disease. Experience in 22 de novo patients.
    Elizan TS; Yahr MD; Moros DA; Mendoza MR; Pang S; Bodian CA
    Arch Neurol; 1989 Dec; 46(12):1275-9. PubMed ID: 2511824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of deprenyl on the progression of disability in early Parkinson's disease.
    Parkinson Study Group
    N Engl J Med; 1989 Nov; 321(20):1364-71. PubMed ID: 2509910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.